参附注射液联合美托洛尔治疗冠心病心力衰竭的临床研究

Clinical Study on Treatment of Coronary Heart Failure with Shengfu Injection and Metoprolol

目的观察参附注射液联合美托洛尔治疗冠心病并心力衰竭的临床疗效和安全性。方法选择冠心病心力衰竭患者64例,随机分为对照组和联合组各32例。对照组常规给予强心甙、利尿剂、血管扩张剂和血管紧张素转换酶抑制剂,心绞痛时加用硝酸酯类药物等西药治疗。联合组在西药常规治疗基础上,应用参附注射液50 mL加入5%葡萄糖100 mL静脉滴注,1次/d;同时联合美托洛尔12.5～25 mg口服,2次/d;两组疗程均为14 d。结果联合组心功能改善的总有效率为87.5%,高于对照组的65.6%,两组比较差别有统计学意义(P<0.05)。联合组心率、左心室舒张末期内径(LVDd)、左心室射血分数(LVEF)均有显著改善(P<0.05);而对照组LVDd和LVEF无显著改善(P>0.05),只有心率明显改善(P<0.05)。结论在西药常规治疗基础上应用参附注射液联合美托洛尔治疗冠心病心力衰竭有协同作用,可明显改善患者的左心功能,有效改善患者的临床症状和生活质量,值得在临床推广应用。

Objective observe the curative effect and safety of treatment of CHF with shenfu injection and metoprolol.Methods 64 cases of such patient were divided into two groups randomly.The test group was treated with shenfu injection of 50 mL qd.and metoprolol of 12.5~ 25 mg bid.for twice weeks as a course on the bases of control group. Results The total effective rate was 87.5% that was higher than that of control group of 65.5% with P〈0.05.The LVDd and LVEF were better in test group than those in control group with P〈0.05. Conclusion This combination method might improve the LHF and clinical symptom and life quality that should be used in clinic.